Provided by Tiger Trade Technology Pte. Ltd.

Context Therapeutics Inc.

2.28
+0.02000.88%
Post-market: 2.24-0.0400-1.75%19:59 EST
Volume:2.30M
Turnover:5.10M
Market Cap:209.48M
PE:-7.92
High:2.33
Open:2.27
Low:2.02
Close:2.26
52wk High:2.85
52wk Low:0.4900
Shares:91.88M
Float Shares:39.87M
Volume Ratio:1.08
T/O Rate:5.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2878
EPS(LYR):-0.4575
ROE:-33.68%
ROA:-22.81%
PB:2.86
PE(LYR):-4.98

Loading ...

Context Therapeutics Highlights T Cell Engager Pipeline Strategy

TIPRANKS
·
Jan 08

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Reuters
·
Dec 22, 2025

ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn

Reuters
·
Dec 17, 2025

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

THOMSON REUTERS
·
Dec 17, 2025

Context Therapeutics Advances CT-95 and CT-202 Programs Toward Clinical Trials

Reuters
·
Nov 07, 2025

Context Therapeutics Reports Improved Quarterly Results

TIPRANKS
·
Nov 06, 2025

Context Therapeutics reports Q3 results and advances lead bispecific antibody trials

Reuters
·
Nov 06, 2025

Context Therapeutics Inc. Q3 Basic EPS USD -0.1

THOMSON REUTERS
·
Nov 06, 2025

Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study

TIPRANKS
·
Oct 28, 2025

BRIEF-Context Therapeutics Amends Sales Deal, May Sell Up To $75 Million in Common Stock – SEC Filing

Reuters
·
Oct 25, 2025

Context Therapeutics: Amends Sales Agreement, May Offer & Sell From Time to Time Common Stock of up to $75 Mln - SEC Filing

THOMSON REUTERS
·
Oct 25, 2025

Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025

Reuters
·
Oct 06, 2025

BRIEF-Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule

Reuters
·
Oct 04, 2025

Context Therapeutics Grants Stock Options to New Employee as Inducement Under Nasdaq Rule

Reuters
·
Oct 04, 2025

Context Therapeutics Gains 11%, Insider Trades Reap Benefit

Simply Wall St.
·
Oct 03, 2025

Context Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
Sep 18, 2025

Context Therapeutics Inc. Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Reuters
·
Sep 02, 2025

Context Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $4 From $5

THOMSON REUTERS
·
Aug 07, 2025

Context Therapeutics Q2 net loss widens, cash funds ops into 2027

Reuters
·
Aug 07, 2025

Context Therapeutics Inc - Expects Its Cash and Cash Equivalents Will Continue to Fund Operations Into 2027

THOMSON REUTERS
·
Aug 07, 2025